Irinotecan Accord

Irinotecan, the active ingredient in Irinotecan Accord, is a topoisomerase I inhibitor presented as an intravenous solution for intravenous use. It treats metastatic colorectal cancer and is used as adjuvant therapy for colon cancer in adult patients.

GNH USA supplies Irinotecan Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Irinotecan is employed in the management of colorectal cancer, targeting tumor cells through inhibition of DNA replication.

- Metastatic colorectal cancer: improves survival as part of combination chemotherapy regimens. - Adjuvant therapy for colon cancer: reduces risk of disease recurrence after surgical resection. - Locally advanced colorectal cancer: used in neoadjuvant regimens to shrink tumors before surgery.

Irinotecan may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Diarrhea: often severe and may require antidiarrheal therapy. - Nausea: may be accompanied by vomiting. - Neutropenia: reduced white blood cell count increasing infection risk. - Alopecia: hair loss during treatment.

Serious or Rare Side Effects: - Severe neutropenic infection: febrile neutropenia requiring hospitalization. - Acute cholinergic syndrome: abdominal cramps, sweating, and bradycardia. - Hypersensitivity reactions: rash, dyspnea, or anaphylaxis.

Before initiating therapy, clinicians should assess patient-specific risk factors and monitor for toxicity.

- Monitor blood counts: regular CBC to detect neutropenia. - Assess liver function: dose adjustments may be needed for hepatic impairment. - Evaluate renal function: consider renal status before administration. - Avoid in pregnancy: contraindicated due to fetal risk; use effective contraception. - Use anti‑diarrheal prophylaxis: loperamide may be prescribed to manage early diarrhea. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan interacts with several drug classes that can alter its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce irinotecan exposure. - UGT1A1 inhibitors (e.g., atazanavir): can increase risk of severe neutropenia and diarrhea.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): increased bleeding risk, monitor INR. - Other myelosuppressive agents: additive bone marrow suppression. - Anticholinergic drugs: may exacerbate cholinergic syndrome.